Skip to main content
SpringerLink
Log in

Efficacy and safety of choline alphoscerate (cereton) in patients with parkinson’s disease with cognitive impairments

  • Published:
Neuroscience and Behavioral Physiology Aims and scope Submit manuscript

An open 10-day study in which the therapeutic actions of Cereton were compared with those of piracetam was performed. Cereton was used in 40 patients (experimental group) at a dose of 1000 mg, while piracetam was used in 20 patients at a dose of 2000 mg; both agents were given as intravenous infusions in 200 ml of physiological saline on the background of antiparkinsonism agents. Patients’ status was evaluated using a complex of psychometric scales and neuropsychological tests, along with tools to assess the severity of the main symptoms of parkinsonism, side effects, and quality of life. Use of Cereton produced marked and moderate improvements in the state of cognitive functions more frequently than piracetam (40% and 25%, respectively), while the incidence of deterioration was lower (5% and 15%, p < 0.05). Cereton was very well tolerated by the patients: brief and short-term side effects were seen in only six patients (15%).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Zh. M. Glozman, Quantitative Assessment of Neuropsychological Study Data [in Russian], Moscow (1999).

  2. V. V. Zakharov, I. V. Damulin, and N. N. Yakhno, “Cognitive impairments in patients with Parkinson’s disease,” Zh. Nevrol. Psikhiat., 1, 13–19 (2005).

    Google Scholar 

  3. O. S. Levin, “Mental disorders in patients with Parkinson’s disease and their correction,” in: Extrapyramidal Disorders. Handbook for Diagnosis and Treatment [in Russian], Medpress-Inform, Moscow (2002), pp. 125–151.

  4. O. S. Levin and N. V. Fedorova, Parkinson’s Disease [in Russian], Moscow (2006).

  5. O. S. Levin, L. A. Batukaeva, and I. G. Smolentseva, “Diagnosis and treatment of dementia in Parkinson’s disease,” Zh. Nevrol. Psikhiat., 6, 85–91 (2008).

    Google Scholar 

  6. I. V. Litvinenko, Parkinson’s Disease [in Russian], Moscow (2006).

  7. A. R. Luriya, Higher Cortical Functions in Humans and theirImpairments in Local Brain Lesions [in Russian], Moscow State University, Moscow (1969).

    Google Scholar 

  8. A. Yu. Panasyuk, An Adapted Variant of the Wechsler Test [in Russian], Research Institute Psychiatry, Moscow (1983).

    Google Scholar 

  9. D. Aarsland, K. Andersen, J. P. Larsen, et al., “Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study,” Arch. Neurol., 60, 387–392 (2003).

    Article  PubMed  Google Scholar 

  10. F. Amenta, L. Parnetti,V. Gallasi, et al., “Treatment of cognitive dysfunction associated with Alzheimer disease with cholinergic precursors,” Mech. Aging Dev., 122, 2025 (2001).

    Article  CAS  PubMed  Google Scholar 

  11. R. Brooks, R. Rabin, and F. de Charro, The Measurement and Valuation of Health Status Using EQ-5D, Kluwer Academic Publishers (2003).

  12. J. L. Cummings, “Cholinesterase inhibitors for treatment of dementia associated with Parkinson’s disease,” J. Neurol. Neurosurg. Psychiat., 76, 903–904 (2005).

    Article  CAS  PubMed  Google Scholar 

  13. M. Emre, D. Aarsland, A. Albanese, et al., “Rivastigmine for dementia associated with Parkinson’s disease,” New Engl. J. Med., 351, 2509–2518 (2004).

    Article  CAS  PubMed  Google Scholar 

  14. M. Emre, D. Aarsland, R. Brown, et al., “Clinical diagnostic criteria for dementia associated with Parkinson disease,” Mov. Dis., 22, 1689–1707 (2007).

    Article  Google Scholar 

  15. S. Fahn and R. L. Elton, “Unified Rating Scale for Parkinson’s Disease,” in: Recent developments in Parkinson’s Disease, S. Fahn and C. D. Marsden (eds.), Macmillan, Florham Park, New York, pp. 153–163.

  16. M. F. Folstein, S. E. Folstein, and P. R. McHugh, “Mini-mental status,” J. Psychiat. Res., 12, 189–196 (1975).

    Article  CAS  PubMed  Google Scholar 

  17. W. Gibb and A. Lees, “The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease,” J. Neurol. Neurosurg. Psychiat., 51, 745–752 (1988).

    Article  CAS  PubMed  Google Scholar 

  18. M. A. Hely, J. G. Morris, W. G. Reid, et al., “Sydney multicenter study of Parkinson’s disease,” Mov. Dis., 23, 837–844 (2008).

    Article  Google Scholar 

  19. M. Hoehn and M. D. Jahr, “Parkinsonism: onset, progression and mortality,” Neurology, 17, No. 5, 427–442 (1967).

    CAS  PubMed  Google Scholar 

  20. H. Lehfeld and H. Erzigkeit, “The SKT-A Short Cognitive Performance Test for Assessing Deficits of Memory and Attention,” Int. Psychogeriat., 9, 115–121 (1997).

    Article  Google Scholar 

  21. P. J. Manos and R. Wu, “The ten point clock test,” Int. J. Psych. Med., 24, 229–244 (1994).

    Article  CAS  Google Scholar 

  22. L. Parnetti, F. Mignini, D. Tomasssoni, et al., “Cholinergic precursors in the treatment of cognitive impairment of vascular origin,” J. Neurol. Sci., 257, 264–269 (2007).

    Article  CAS  PubMed  Google Scholar 

  23. E. Perry, M. Walker, J. Grace, and R. Perry, “Acetylcholine in mind: a neurotransmitter correlate of consciousness?” Trends Neurosci., 22, 273–280 (1999).

    Article  CAS  PubMed  Google Scholar 

  24. S. E. Starkstein and M. Merello, Psychiatric and Cognitive Disorders in Parkinson’s Disease, Cambridge University Press, Cambridge (2002).

    Book  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Russian Postgraduate Medical Academy; Center for Extrapyramidal Diseases, Moscow, Russia

    O. S. Levin, L. A. Batukaeva, M. A. Anikina & N. A. Yunishchenko

Authors
  1. O. S. Levin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. A. Batukaeva
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. A. Anikina
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N. A. Yunishchenko
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to O. S. Levin.

Additional information

Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 109, No. 11, pp. 42–46, November, 2009.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Levin, O.S., Batukaeva, L.A., Anikina, M.A. et al. Efficacy and safety of choline alphoscerate (cereton) in patients with parkinson’s disease with cognitive impairments. Neurosci Behav Physi 41, 47–51 (2011). https://doi.org/10.1007/s11055-010-9377-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11055-010-9377-2

Key Words

Search

Navigation